Fig. 4
The alleviation of TBI-induced intracellular ROS generation by commercially available drugs. Mice were intraperitoneally administered the clinical dosage (10 μg/kg of body weight/day) of G-CSF once-daily for 4 times and RP once a week for 3 times (GRP #4) starting within 2 h after a 7.25-Gy dose of TBI. Mice treated with TBI only received injections of the normal saline solution as vehicle. “7.25 Gy + GRP” and “7.25 Gy” indicate the results of TBI mice with and without GRP #4, respectively. a The levels of ROS in splenic cells (SPCs) detected by the CM-H2DCFDA mean fluorescence intensity (MFI) (n = 5 in each group) and b the representative histogram of ROS levels by flow cytometry. c The levels of ROS in BMCs detected by the CM-H2DCFDA MFI (n = 5 in each group) and d the representative histogram of ROS levels by flow cytometry. e The representative flow cytometry plots of forward and side scatter of BMCs are shown. The data are expressed as the means ± SD. Statistically significant differences were evaluated by one-way ANOVA and the multiple comparison tests (**P < 0.01, *P < 0.05)